Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kyntra Bio (KYNB) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Kyntra Bio (KYNB) over the last 7 years, with Q3 2025 value amounting to -$58000.0.

  • Kyntra Bio's Other Operating Expenses rose 2266.67% to -$58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 14705.34%. This contributed to the annual value of $15.5 million for FY2024, which is 29159.52% up from last year.
  • Kyntra Bio's Other Operating Expenses amounted to -$58000.0 in Q3 2025, which was up 2266.67% from $85000.0 recorded in Q2 2025.
  • Kyntra Bio's Other Operating Expenses' 5-year high stood at $21.3 million during Q1 2024, with a 5-year trough of -$9.5 million in Q4 2023.
  • Moreover, its 5-year median value for Other Operating Expenses was $3.3 million (2021), whereas its average is $2.8 million.
  • As far as peak fluctuations go, Kyntra Bio's Other Operating Expenses plummeted by 29246.7% in 2023, and later skyrocketed by 51137.21% in 2024.
  • Over the past 5 years, Kyntra Bio's Other Operating Expenses (Quarter) stood at $3.1 million in 2021, then soared by 57.6% to $4.9 million in 2022, then plummeted by 292.47% to -$9.5 million in 2023, then surged by 37.84% to -$5.9 million in 2024, then surged by 99.02% to -$58000.0 in 2025.
  • Its Other Operating Expenses stands at -$58000.0 for Q3 2025, versus $85000.0 for Q2 2025 and $252000.0 for Q1 2025.